10x Genomics, Inc. (TXG) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-13
How it makes money
It earns revenue by selling Chromium, Visium, and Xenium instruments to researchers, which then drives recurring sales of 424,000 consumable reactions per year.
The business operates a razor-and-blade model where an installed base of 8,046 instruments creates demand for proprietary microfluidic chips and reagents. In 2025, these sales generated $642.8 million in revenue.
Chromium single-cell solutions represent the largest portion of the business, with 6,477 cumulative instruments sold compared to 1,015 for Visium and 554 for Xenium.
What protects it: the moat
It protects its margins through an installed base of 8,046 instruments and a scientific moat of 10,000 peer-reviewed articles using its proprietary barcodes.
The company relies on a high degree of scientific acceptance to maintain its market position. Researchers use its proprietary gel beads and unique barcodes to distinguish biological contents, creating data sets that are difficult to replicate on rival platforms.
Management claims its Resolution and Scale imperatives provide a technical advantage that enables measuring millions of single cells or tissue sample positions simultaneously.
What growth costs
It spent $9.2 million in cash and $13.5 million in stock to acquire Scale Bio while managing a $43.5 million net loss.
Growth is driven by both internal R&D and strategic acquisitions. The 2025 acquisition of Scale Bio includes contingent payments of up to $30.0 million if specific milestones are met, alongside an expected $20.0 million payment in 2026.
The company must also reinvest to manage product transitions, such as the Chromium X Series, which can temporarily impact the unit volume of existing instruments.
What could damage it
Earnings face impairment from a high dependency on Chromium solutions and fluctuations in government research funding that supports its customer base.
The business is sensitive to the procurement and budgeting cycles of academic institutions. Any reduction in government funding directly reduces the ability of researchers to purchase instruments or the consumables required for experiments.
Additionally, the rapid introduction of new versions of existing products risks cannibalizing sales or causing customers to postpone purchases until new capabilities are available.
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.